Cathie Wood favors the stocks of companies with disruptive potential. As a result, Wood's ARK Invest exchange-traded funds (ETFs) have significant positions in some of the highest-profile stock-split stocks of 2022. Here are two stock-split stocks that Wood loves -- and two more that she likes. Read More...
Motley Fool
3 IPO Stocks That You Want to Own
Three Motley Fool contributors have joined this roundtable to scour the market for some exciting initial public offerings (IPOs) in the healthcare field. Alex Carchidi (Amylyx Pharmaceuticals): Amylyx is worth owning because there’s a solid chance it’ll soon commercialize the first treatment for amyotrophic lateral sclerosis (ALS) that prolongs survival time while also slowing the disease’s progression. Its medicine, AMX0035, has been approved for sale in Canada since late July, and regulators at the U.S. Food and Drug Administration will weigh in on the company’s application for commercialization on Sept. 29.
